AMGEN Inc.

AMGN

$211.32

-8.5% last 12 months

Market Cap

$113 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$198.64 - $268.39

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

20.2x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$6.96 (3.46%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $113 Billion
Enterprise Value $138 Billion
Dividend Yield $6.96 (3.46%)
1 Year Return -5.0%
52-Week High $268.39
52-Week Low $198.64
Beta 0.63
Outstanding Shares 563 Million
Avg 30 Day Volume 3.01 Million

Valuation

P/E Ratio 20.2
PEG -298.01
Earnings per Share $9.70
Price to Sales Ratio 4.7
Price to Book Ratio 15.09
Revenue to Enterprise Value 5.35
EBIT to Enterprise Value 15.59
Total Debt to Enterprise Value 0.27
Debt to Equity 4.57

Profitability

Revenue $25.8 Billion
Gross Profit $19.4 Billion
EBIT $8.85 Billion
Net Income $5.61 Billion
Profit Margin 21.77%
Quarterly Earnings Growth (YoY) -6.8%
Return on Equity 68.26%
Return on Assets 8.63%
Return on Invested Capital 17.64%

Insider trades

No purchases

13,360 shares sold (4 transactions)

No purchases

2,750 shares sold (2 transactions)

No purchases

No sells

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

About AMGEN Inc.

CEO: Robert Bradway

Employees: 22,000

Industry: Biological Product (except Diagnostic) Manufacturing

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Similar stocks

Pfizer Inc.
Glaxosmithkline plc - ADR
Gilead Sciences, Inc.
Biogen Inc
Abbvie Inc
Alexion Pharmaceuticals Inc.
Johnson & Johnson
Illumina Inc
Lilly(Eli) & Co

News